http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2445791-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dcce39a20bef16c3f04497659caba40f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_afd43e12353298376fd7642260c1dbca http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_84d9adaa7e7ce01ce8020f5c721aba10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2cf7f3f36d20185ce15a2d1f04d5fdc1 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D241-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 |
| filingDate | 2007-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3dd28f0079aa5cb36c83a903a1fc19c5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b03d947bf886b1505da1137b1d66006a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53f0e8243e81e38000c6de5812ffbd00 |
| publicationDate | 2014-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2445791-T3 |
| titleOfInvention | Hetero-cyclic compounds and their use as glycogen synthase kinase 3 inhibitors |
| abstract | A heterocyclic compound of the general formula (I) is the stereoisomers and / or physiologically acceptable acid addition salts thereof, whereA is selected from the group consisting of NH, N-C1-C4 alkyl and C1-C4 N-halogenated alkyl (preferably fluorinated); X1 is N; X2 is selected from the group consisting of CH, CR2 and N; X3 is selected from the group consisting of CH, CR2 and N; X4, X5, X6 and X7 are independently selected from each other from the group consisting of CH, CR1 and N, Y3, Y4, Y5 and Y6 are independently selected from each other from the group consisting of a C, CH, CR3 and N, resulting in a 6-member C-ring; or one of Y3, Y4, Y5 and Y6 is part of the bridge bond between its two adjacent atoms that results in a 5-member C-ring; or with Y5> = Y6> = C, then Y5 and Y6 can form together with the ring of 5 or 6 members C, a fused cyclic ring having 5 or 6 ring members, including Y5 and Y6 as ring members and comprising atoms of C as ring members or instead of an atom of C may contain 0, 1, 2 or 3 members of heteroaromatic rings, independently selecting each other from the group consisting of N, O and S, where the condensed ring system it can be substituted with 1, 2 or 3 residues R3, independently having a meaning as defined below: n is the number of residues R3 and is selected from 0, 1, 2, 3 or 4; m is the number of residues R2 and is selected from 0, 1 or 2; or is the number of residues R1 and is selected from 0, 1, 2, 3 or 4; R1, R3 are independently selected from each other, and independently in each case, from the group consisting of NH2, NH-C1 alkyl -C6, NRaRb, OH,> = O, C1-C6 alkoxy, C1-C6 haloalkoxy, halogen, C1-C4 alkyl, C3-C7 cycloalkyl, C2-C4 alkenyl, halogenated C1-C4 alkyl (preferably fluorinated), C3- cycloalkyl C7halogenated (preferably fluorinated), halogenated C2-C4 alkenyl (preferably fluorinated), formyl, C1-C6 alkylcarbonyl, C1-C6 alkyl-NRaRb and an aromatic radical Ar, which is selected from the group consisting of phenyl and a heteroaromatic radical linked to 5 or 6-member No. C, comprising 1 nitrogen atom as a ring member and 0.1, 2 or 3 additional heteroatoms, independently selected from O, S and N, as ring members, wherein Ar is unsubstituted or carries one or two radicals R1a; R2 is independently selected in each case from the group consisting of halogen, CN, C1-C6 alkyl, halogenated C1-C6 alkyl (preferably fluorinated), NRaRb; or for m> = 2 or 3, two of R2 to X2 and X3 can form condensed aliphatic cyclic assemblies of 5 or 6 members which may contain 1 or 2 heteroatoms as ring members, selected from the group consisting of N, O and S and which may be substituted with 1, 2 or 3 residues R3, independently of each other, having a meaning as defined above; R1a is independently selected from each other, and independently in each case, from the group consisting of halogen, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, halogenated (preferably fluorinated) C1-C6 alkyl, halogenated C3-C6 cycloalkyl (preferably fluorinated), halogenated C1-C6 alkoxy (preferably fluorinated), NRaRb, 1-aziridinyl, azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl and homopiperidin-1-yl , a phenyl group or a 5- or 6-membered aromatic or heteroaromatic radical linked to C comprising 1 nitrogen atom as a ring member and 0, 1, 2 or 3 additional heteroatoms independently selected from O, S and N, as ring members, wherein phenyl and the heteroaromatic radical are, independently of each other, unsubstituted or substituted with 1, 2, 3 or 4 radicals selected from halogen, cyano, C1-C4 alkyl, halogenated (preferably fluorinated) C1-C4 alkyl, alkoxy C1-C4 and halogenated C1-C4 alkoxy (pref eridably fluoridated); Ra, Rb are independently selected from the group consisting of H, C1-C4 alkyl, halogenated C1-C4 alkyl (preferably fluorinated) and C1-C4 alkoxy or may form, together with the nitrogen atom to which they are attached, an N- ring 4, 5, 6 or 7-membered saturated or unsaturated heterocyclic, which may carry an additional heteroatom selected from the group consisting of O, S and N as a ring member; R4 is selected from the group consisting of H, C1 alkyl -C4 and halogenated C1-C6 alkyl (preferably fluorinated); except for 1- (3-methyl-pyridin-2-yl) -3- (2-methyl-quinolin-4-yl) -urea. |
| priorityDate | 2006-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 875.